Nebivolol Aurovitas (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Aurovitas, is a selective β1‑adrenergic antagonist presented as a tablet for oral use. It is indicated for the management of essential hypertension and for reducing morbidity in patients with heart failure and reduced ejection fraction, primarily in adult populations.

GNH USA supplies Nebivolol Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide for inclusion in cardiovascular therapeutic formularies and procurement programs, with consistent quality and regulatory compliance.

Nebivolol acts on the cardiovascular system to lower blood pressure and improve cardiac function in specific disease states. - Essential hypertension: reduces systolic and diastolic blood pressure, helping achieve target levels. - Heart failure with reduced ejection fraction: improves ventricular performance and decreases hospitalization risk. - Hypertension in patients with comorbid conditions: provides blood pressure control while offering a favorable metabolic profile.

Nebivolol may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Dizziness or light‑headedness - Fatigue or tiredness - Bradycardia (slow heart rate) - Nasal congestion - Peripheral edema

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Bronchospasm in susceptible individuals - Acute heart failure worsening - Allergic reactions such as rash or angioedema - Liver enzyme elevation or hepatitis

When prescribing Nebivolol, clinicians should consider several precautionary measures to ensure safe use. - Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Heart rate assessment: observe for bradycardia, especially in patients with conduction disorders. - Respiratory caution: use carefully in patients with asthma or chronic obstructive pulmonary disease. - Discontinuation: avoid abrupt withdrawal to prevent rebound hypertension and tachycardia. - Renal or hepatic impairment: dose adjustment may be required based on organ function. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Combined use with other β‑blockers: may cause excessive β‑blockade and severe bradycardia. - Co‑administration with non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): increases risk of heart block and hypotension. - Potent CYP2D6 inhibitors (e.g., paroxetine, quinidine): raise nebivolol plasma levels, enhancing adverse effects.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate antihypertensive effect, requiring blood pressure monitoring. - ACE inhibitors or ARBs: additive blood pressure lowering, monitor for hypotension. - Anti‑arrhythmic agents (e.g., amiodarone): may affect cardiac conduction, observe ECG.